Suppr超能文献

他莫昔芬治疗多囊性肝病:病例报告。

Tamoxifen for the treatment of polycystic liver disease: A case report.

机构信息

Department Nephrology, University Medical Center, Groningen, The Netherlands.

Department Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Medicine (Baltimore). 2021 Aug 13;100(32):e26797. doi: 10.1097/MD.0000000000026797.

Abstract

RATIONALE

Polycystic liver disease is a rare disease characterized by the growth of numerous cysts in the liver. The liver function remains well preserved, but liver volumes can grow very large, and some patients ultimately need a liver transplantation. Other treatment options are limited and there is an unmet need for new therapeutic options.

PATIENT CONCERNS

We describe a 59-year-old patient with pain in the abdomen, especially when bending forward. Five years ago, she was diagnosed with breast cancer and as an incidental finding a couple of large liver cysts were diagnosed, explaining her abdominal pain.

DIAGNOSIS

Polycystic liver disease with several large liver cysts.

INTERVENTIONS

The patient was treated with tamoxifen, an estrogen receptor modulator, as treatment for her hormone receptor positive breast cancer. One of the liver cysts was aspirated.

OUTCOMES

In the 4.6 years after the start of tamoxifen treatment, 20 mg once daily, the volume of her liver cysts decreased remarkably. There was a reduction of combined cyst volume from 311 mL to 22 mL without percutaneous drainage.

LESSONS

Epidemiological as well as experimental evidence supports a pivotal role for estrogens as a driver for growth of polycystic livers. Estrogen antagonism has often been proposed as a therapeutic target, but supporting evidence is lacking in the literature. We hypothesize that the decrease in cyst size in this patient was caused by tamoxifen therapy, suggesting an in vivo antagonistic effect on cystic cholangiocytes. This is an important finding because tamoxifen could be a promising new treatment option for polycystic liver disease.

摘要

背景

多囊肝疾病是一种罕见疾病,其特征是肝脏内生长出许多囊肿。肝脏功能保持良好,但肝体积可能会非常大,一些患者最终需要进行肝移植。其他治疗选择有限,因此需要新的治疗方法。

病例描述

我们描述了一位 59 岁女性患者,她有腹痛,尤其是向前弯腰时。五年前,她被诊断出患有乳腺癌,偶然发现几个大的肝囊肿,这可以解释她的腹痛。

诊断

多囊肝疾病,伴有几个大的肝囊肿。

干预措施

该患者接受了他莫昔芬(一种雌激素受体调节剂)治疗,用于治疗其激素受体阳性乳腺癌。其中一个肝囊肿被抽吸。

结果

在开始使用他莫昔芬治疗后的 4.6 年内,每日一次 20 毫克,她的肝囊肿体积显著减少。联合囊肿体积从 311 毫升减少到 22 毫升,而无需进行经皮引流。

结论

流行病学和实验证据均支持雌激素作为多囊肝生长的驱动因素。雌激素拮抗作用经常被提议作为一种治疗靶点,但文献中缺乏支持证据。我们假设该患者的囊肿大小减小是由于他莫昔芬治疗引起的,这表明其对囊性胆管细胞具有体内拮抗作用。这是一个重要的发现,因为他莫昔芬可能成为多囊肝疾病的一种有前途的新治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57d7/8360467/63b0344581f5/medi-100-e26797-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验